Scientific Retreat – 2013

About Scientific Retreat – 2013

About PCF

This year, the Prostate Cancer Foundation (PCF) is celebrating twenty years of progress in eliminating suffering and death for prostate cancer patients with advanced disease. Since 1993, PCF has generated nearly $550 million to fund more than 2,000 research projects at nearly 200 institutions in 17 countries.

Our continually expanding global research enterprise brings together the brightest minds to collaborate across borders and organization lines. PCF is the source of hope for 16 million men and their families around the world who are affected by this disease.
A few examples of progress attributable to PCF activities in the past
20 years are highlighted below.

Download the 2013 State of the Science Report in PDF format

Prostate Cancer Foundation and 20 Years of Progress

1993 Today
Federal Funding $27 million nearly $550 million
Dedicated Research Labs 3 > 200
SPORE Grants 2 11 (at program peak)
New clinical trials/ year 2 > 60
Tissue banks for research None Multiple tissue banks with 50,000-plus samples
Research career positions/ year ~4 > 100
Funding for nutritional research None $20 million
Nations with dedicated prostate cancer research centers 3 18
Published research articles/ year on prostate cancer 1,646 7,730 (in 2012)

In its twenty years of existence, PCF has continually scouted for and funded the most groundbreaking research for immediate impact for prostate cancer patients with advanced disease. PCF stimulated the research community and the biopharma sector, accelerating the development of six new FDA-approved drugs for prostate cancer patients in the past three years.

• Jevtana (Cabazitaxel, Sanofi Oncology)
• Provenge (Dendreon Corporation)
• Xgeva (Denosumab, Amgen)
• Xofigo (Alpharadin, Bayer Healthcare and Algeta)
• Xtandi (Enzalutamide, Medivation-Astellas)
• Zytiga (Abiraterone Acetate, J&J)

In 2012 alone, we

issued 199 research award checks totaling $29.4 million
expanded our international research enterprise
launched two $10 million Dream Teams for three years, enabled by the support of Stand Up to Cancer, Movember,
and PCF donors
• raised $47 million, nine percent above our aggressive target of $43 million
gained unrestricted researchsupport from 32 biotechnology and pharmaceutical companies totaling $1.8

launched the Intermediate Clinical Endpoints for Cancer of the Prostate (ICECaP) initiative, that engages global
partners in Europe, Australasia and North America- academicians. pharma, cooperative groups and the FDA to create
a database of 30,000-50,000 patients on clinical trials

Looking ahead, PCF continues to invest in research benefiting prostate cancer patients, globally:

PCF is currently funding 34 early-stage clinical trials
PCF is expanding globally, with the recent launches of PCF China, PCF Canada and PCF Norway. We are
exploring opportunities in Netherlands and Brazil
In 2013, PCF will host its first PCF-Europe Research Symposium
We are formulating a Global Treatment Science Network (TSN) with the capacity to integrate real-time insights from
the clinic and build on our successes and existing assets

We continue to leverage the knowledge, insights, and data from our 125 Young Investigators, 45 Challenge Awards teams, and 48 Creativity Award recipients. This and info gleaned from our Global Knowledge Exchange Enterprise has helped us design the agenda for the 20th Annual PCF Scientific Retreat.

For the past 19 years, the PCF Annual Scientific Retreat highlights cutting-edge research as well as current challenges facing the prostate cancer research and patient communities through formal lectures, panel discussions, workshops, discussions, and poster presentations. PCF assembles an outstanding roster of speakers in a comprehensive scientific program that showcases the state-of-the-art, novel approaches and technologies being used in the laboratory, innovative preclinical science, clinical trial results, and more.

“Attending the (PCF) Scientific Retreat is a little like drinking from a fire hose. The problem isn’t that there isn’t enough information, but it clearly tests the capacity of any one person to drink it all in. It’s the place where you learn about what’s coming down the pike. It’s like putting your ear to the rail before you actually hear the train coming- it’s where you first hear rumblings about what will be in the public domain two or three years later.”

-Joel Nelson, MD
University of Pittsburgh